Ocular Sciences v. Bausch & Lomb
This article was originally published in The Gray Sheet
Lawsuit filed in California state court seeks injunctive relief, compensatory and punitive damages from Bausch & Lomb for tortious interference with the March 20 definitive merger agreement between Ocular and Wesley Jessen. The suit is the latest salvo in a tug of war for Wesley Jessen. B&L launched a hostile $34-per-share takeover bid for Wesley Jessen April 3 and filed a lawsuit against Wesley Jessen and Ocular seeking injunctive relief against the merger in the Court of Chancery of Delaware (1"The Gray Sheet" April 10, In Brief)
You may also be interested in...
Firm commences hostile takeover bid for tinted contact lens maker Wesley Jessen April 3 via $34-per-share tender offer (1"The Gray Sheet" April 3, In Brief). Separately, B&L filed a lawsuit in the Court of Chancery of Delaware against Wesley Jessen and Ocular Sciences seeking "injunctive relief" against the Wesley Jessen/Ocular Sciences merger agreement of March 20, redemption of Wesley Jessen's "poison pill" anti-takeover provisions and "a declaration that any breakup fee Ocular receives it holds as a constructive trustee," B&L states
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.